Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 2.63M | 3.75M | 140.14M | 5.09M | 13.16M | 0.00 |
Gross Profit | 2.63M | 3.75M | 124.52M | 4.46M | 12.85M | -303.00K |
EBITDA | -25.78M | -18.58M | 73.48M | -59.91M | -31.41M | -51.15M |
Net Income | -27.09M | -21.29M | 67.04M | -62.81M | -32.87M | -55.19M |
Balance Sheet | ||||||
Total Assets | 67.92M | 90.64M | 128.41M | 87.81M | 119.84M | 102.54M |
Cash, Cash Equivalents and Short-Term Investments | 40.61M | 59.30M | 74.36M | 73.50M | 104.48M | 93.04M |
Total Debt | 2.49M | 16.27M | 15.08M | 48.60M | 43.63M | 19.84M |
Total Liabilities | 17.38M | 35.57M | 55.45M | 84.58M | 78.58M | 79.78M |
Stockholders Equity | 50.53M | 55.08M | 72.96M | 3.23M | 41.26M | 22.76M |
Cash Flow | ||||||
Free Cash Flow | -27.47M | -24.01M | 60.16M | -79.89M | -55.73M | -49.36M |
Operating Cash Flow | -27.47M | -24.01M | 60.16M | -79.88M | -54.56M | -49.35M |
Investing Cash Flow | 13.14M | 6.15M | -34.88M | -27.39M | -1.17M | 6.47M |
Financing Cash Flow | -14.21M | -139.00K | -36.72M | 48.60M | 67.12M | 94.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
54 Neutral | $27.96M | ― | -2.12% | ― | 12.82% | 96.46% | |
51 Neutral | $7.50B | 0.32 | -61.87% | 2.27% | 17.10% | 1.59% | |
45 Neutral | $20.69M | ― | -203.11% | ― | -41.45% | 40.69% | |
41 Neutral | $5.90M | ― | -59.14% | ― | -33.10% | 71.37% | |
40 Underperform | $28.10M | ― | -43.47% | ― | -98.13% | -129.06% | |
31 Underperform | $32.58M | ― | -576.46% | ― | ― | 38.50% | |
$222.77M | 0.08 | 57.63% | ― | ― | ― |
On June 25, 2025, SCYNEXIS, Inc. conducted its Annual Meeting of Stockholders, where key decisions were made regarding the company’s governance and financial oversight. The meeting resulted in the re-election of seven directors, the ratification of Deloitte & Touche LLP as the independent accounting firm for the fiscal year ending December 31, 2025, and the approval of executive compensation as outlined in the company’s proxy statement. These decisions are crucial for SCYNEXIS’s operational continuity and strategic planning, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.
On June 20, 2025, SCYNEXIS received a notification from Nasdaq regarding its failure to meet the minimum bid price requirement for its common stock, which has been below $1.00 for 30 consecutive business days. SCYNEXIS has until December 17, 2025, to regain compliance, with options including a reverse stock split if necessary. Failure to comply could result in delisting, although SCYNEXIS may appeal any delisting decision.
The most recent analyst rating on (SCYX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on SCYNEXIS stock, see the SCYX Stock Forecast page.